{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T06:29:57Z","timestamp":1769149797475,"version":"3.49.0"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2022.3079","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T15:36:49Z","timestamp":1647877009000},"page":"e223079","source":"Crossref","is-referenced-by-count":12,"title":["Comparison of Trials Using Ivermectin for COVID-19 Between Regions With High and Low Prevalence of Strongyloidiasis"],"prefix":"10.1001","volume":"5","author":[{"given":"Avi","family":"Bitterman","sequence":"first","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caitlin Pestana","family":"Martins","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine, Bronx, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahuva","family":"Cices","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makarand Prasad","family":"Nadendla","sequence":"additional","affiliation":[{"name":"University of Denver, Denver, Colorado"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2022,3,21]]},"reference":[{"issue":"11","key":"zoi220123r1","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1017\/S003118201100120X","article-title":"Epidemiological aspects of strongyloidiasis in Brazil.","volume":"138","author":"Paula","year":"2011","journal-title":"Parasitology"},{"issue":"8","key":"zoi220123r2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003018","article-title":"Strongyloidiasis\u2014an insight into its global prevalence and management.","volume":"8","author":"Puthiyakunnon","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"zoi220123r3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s12639-019-01090-x","article-title":"Strongyloides stercoralis hyperinfection syndrome: a deeper understanding of a neglected disease.","volume":"43","author":"Vasquez-Rios","year":"2019","journal-title":"J Parasit Dis"},{"issue":"6","key":"zoi220123r4","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens9060468","article-title":"The global prevalence of Strongyloides stercoralis infection.","volume":"9","author":"Buonfrate","year":"2020","journal-title":"Pathogens"},{"issue":"11","key":"zoi220123r5","first-page":"766","article-title":"Strongyloides stercoralis hyperinfection syndrome and disseminated disease.","volume":"7","author":"Kassalik","year":"2011","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"4","key":"zoi220123r6","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.trstmh.2008.01.020","article-title":"Strongyloides hyperinfection syndrome: an emerging global infectious disease.","volume":"102","author":"Marcos","year":"2008","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"7","key":"zoi220123r7","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1111\/imj.2018.48.issue-7","article-title":"Fatal Strongyloides hyperinfection syndrome in an immunocompetent adult with review of the literature.","volume":"48","author":"Chan","year":"2018","journal-title":"Intern Med J"},{"issue":"1","key":"zoi220123r8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/20009666.2020.1824333","article-title":"Parasitic necrotizing pneumonia in an immunocompetent patient in United States.","volume":"11","author":"Gopalakrishna","year":"2021","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"zoi220123r9","article-title":"Strongyloides hyperinfection syndrome in an immunocompetent host resulting in bandemia and death.","volume":"2017","author":"Myint","year":"2017","journal-title":"BMJ Case Rep"},{"issue":"6","key":"zoi220123r10","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s15010-015-0799-1","article-title":"Strongyloides stercoralis hyperinfection syndrome: a case series and a review of the literature.","volume":"43","author":"Geri","year":"2015","journal-title":"Infection"},{"issue":"4","key":"zoi220123r11","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.4269\/ajtmh.20-0699","article-title":"Case report: disseminated strongyloidiasis in a patient with COVID-19.","volume":"103","author":"Lier","year":"2020","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"zoi220123r12","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s15010-020-01522-4","article-title":"Strongyloides infection manifested during immunosuppressive therapy for SARS-CoV-2 pneumonia.","volume":"49","author":"Marchese","year":"2021","journal-title":"Infection"},{"issue":"S1","key":"zoi220123r13","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/ijlh.v43.s1","article-title":"Evaluation of eosinopenia as a diagnostic and prognostic indicator in COVID-19 infection.","volume":"43","author":"Soni","year":"2021","journal-title":"Int J Lab Hematol"},{"issue":"3","key":"zoi220123r14","first-page":"194","article-title":"Strongyloidiasis: a multifaceted disease.","volume":"7","author":"Ganesh","year":"2011","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"7","key":"zoi220123r15","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1001\/jama.2020.13170","article-title":"COVID-19 and dexamethasone: a potential strategy to avoid steroid-related Strongyloides hyperinfection.","volume":"324","author":"Stauffer","year":"2020","journal-title":"JAMA"},{"issue":"4","key":"zoi220123r16","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.1097\/MJT.0000000000001402","article-title":"Ivermectin for prevention and treatment of COVID-19 infection: a systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines.","volume":"28","author":"Bryant","year":"2021","journal-title":"Am J Ther"},{"issue":"1","key":"zoi220123r19","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1186\/s12879-021-06348-5","article-title":"Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial.","volume":"21","author":"Vallejos","year":"2021","journal-title":"BMC Infect Dis"},{"issue":"11","key":"zoi220123r20","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1038\/s41591-021-01535-y","article-title":"The lesson of ivermectin: meta-analyses based on summary data alone are inherently unreliable.","volume":"27","author":"Lawrence","year":"2021","journal-title":"Nat Med"},{"issue":"4","key":"zoi220123r22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial.","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"issue":"3","key":"zoi220123r23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package.","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Software"},{"issue":"43","key":"zoi220123r24","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.21105\/joss","article-title":"Welcome to the tidyverse.","volume":"4","author":"Wickham","year":"2019","journal-title":"J Open Source Software"},{"issue":"10","key":"zoi220123r29","doi-asserted-by":"publisher","first-page":"5833","DOI":"10.1002\/jmv.v93.10","article-title":"Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: a randomized controlled study.","volume":"93","author":"Abd-Elsalam","year":"2021","journal-title":"J Med Virol"},{"key":"zoi220123r30","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2020.101906","article-title":"Risk of hospitalization for COVID-19 outpatients treated with various drug regimens in Brazil: comparative analysis.","volume":"38","author":"Szente Fonseca","year":"2020","journal-title":"Travel Med Infect Dis"},{"key":"zoi220123r31","article-title":"Efficacy and safety of ivermectin and hydroxychloroquine in patients with severe COVID-19: a randomized controlled trial.","author":"Gonzalez","journal-title":"medRxiv"},{"key":"zoi220123r32","article-title":"Controlled randomized clinical trial on using ivermectin with doxycycline for treating COVID-19 patients in Baghdad, Iraq.","author":"Hashim","journal-title":"medRxiv"},{"issue":"14","key":"zoi220123r33","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1001\/jama.2021.3071","article-title":"Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial.","volume":"325","author":"L\u00f3pez-Medina","year":"2021","journal-title":"JAMA"},{"issue":"5","key":"zoi220123r34","doi-asserted-by":"crossref","DOI":"10.1177\/03000605211013550","article-title":"Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial.","volume":"49","author":"Mahmud","year":"2021","journal-title":"J Int Med Res"},{"issue":"1","key":"zoi220123r35","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/s12879-021-06104-9","article-title":"Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients.","volume":"21","author":"Okumus","year":"2021","journal-title":"BMC Infect Dis"},{"key":"zoi220123r36","doi-asserted-by":"publisher","first-page":"343","DOI":"10.18433\/jpps32105","article-title":"Evaluation of ivermectin as a potential treatment for mild to moderate COVID-19: a double-blind randomized placebo controlled trial in Eastern India.","volume":"24","author":"Ravikirti","year":"2021","journal-title":"J Pharm Pharm Sci"},{"issue":"6","key":"zoi220123r37","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.clinthera.2021.04.007","article-title":"Effects of ivermectin in patients with COVID-19: a multicenter, double-blind, randomized, controlled clinical trial.","volume":"43","author":"Shahbaznejad","year":"2021","journal-title":"Clin Ther"},{"key":"zoi220123r38","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101054","article-title":"Effect of co-infection with intestinal parasites on COVID-19 severity: a prospective observational cohort study.","volume":"39","author":"Wolday","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"7-8","key":"zoi220123r39","first-page":"316","article-title":"Ivermectin treatment for Strongyloides infection in patients with COVID-19.","volume":"47","author":"Biologics Clinical Practice Guidelines Working Group","year":"2021","journal-title":"Can Commun Dis Rep"},{"issue":"1","key":"zoi220123r40","article-title":"Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection.","author":"Henriquez-Camacho","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"zoi220123r21","volume-title":"R: A Language and Environment for Statistical Computing","year":"2021"},{"key":"zoi220123r25","volume-title":"Use R! Series","author":"Wickham","year":"2016"},{"key":"zoi220123r26","doi-asserted-by":"crossref","DOI":"10.1201\/9781003107347","volume-title":"Doing Meta-Analysis With R: A Hands-On Guide","author":"Harrer","year":"2021"},{"key":"zoi220123r27","volume-title":"STATA Statistical Software: Release 17","year":"2021"},{"key":"zoi220123r28","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"key":"zoi220123r17","unstructured":"Director General of Health Malaysia. Kenyataan Akhbar KPK 3 November 2021\u2014Hasil Dapatan Kajian Keberkesanan Rawatan Ivermectin Untuk Pesakit COVID-19 Berisiko Tinggi (I-TECH Study) [in Malaysian]. November 3, 2021. Accessed November 6, 2021. https:\/\/kpkesihatan.com\/2021\/11\/03\/kenyataan-akhbar-kpk-3-november-2021-hasil-dapatan-kajian-keberkesanan-rawatan-ivermectin-untuk-pesakit-covid-19-berisiko-tinggi-i-tech-study\/"},{"key":"zoi220123r18","unstructured":"Mills? E. Early treatment of COVID-19 with repurposed therapies: the TOGETHER adaptive platform trial. August 21, 2021. Accessed November 3, 2021. https:\/\/rethinkingclinicaltrials.org\/news\/august-6-2021-early-treatment-of-covid-19-with-repurposed-therapies-the-together-adaptive-platform-trial-edward-mills-phd-frcp\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2790173\/bitterman_2022_oi_220123_1646862772.92008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T15:37:05Z","timestamp":1647877025000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2790173"}},"subtitle":["A Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2022,3,21]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.3079","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,21]]}}}